Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

A pilot study of a digital, patient-directed consent process for MSK-IMPACT tumor-normal genetic testing in gynecologic cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVarshini GaliYLYue LiuNVNancy Varice

Discussion

Loading...

Member takes

Overview

Pilot study tests a digital consent process for genetic testing in gynecologic cancer, indicating improved patient empowerment.

Key Points

  • This pilot study aims to evaluate the feasibility and acceptability of a digital, self-guided consent process for genetic testing in gynecologic cancer patients.
  • Developed a digital consent process called 'read and sign' (R&S) for MSK-IMPACT tumor-normal genetic testing
  • Conducted the study in gynecologic surgery and medical oncology clinics, offering R&S consent to eligible patients
  • Followed up with patients at 2, 7, and 14 days to assess consent status and satisfaction.
  • In the gynecologic surgery group, 102 out of 122 patients (84%) consented using R&S, with 59 (58%) on the same day.
  • In medical oncology, 50 out of 51 patients (98%) consented via R&S, with 38 (76%) on the same day.
  • Average time savings included 8 minutes per patient in gynecologic surgery and 14 minutes in medical oncology.

Cite This Study

Gali et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4417f8dhttps://doi.org/10.1200/jco.2026.44.16_suppl.10604
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic testing in endometrial cancer (GenEC): A study on the patient experience with MSK-IMPACT.2026
  2. 2An asynchronous electronic consent for improving consent in research among patients with cancer2025
  3. 3Abstract 6375: Genetic testing station increases access to germline genetic testing2024 · 1 citations
  4. 4Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT)2025
  5. 5Supporting utility and representation in genomics-based clinical trial enrollment (SURGE): Interim findings.2026